(Q73665855)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

main subject

phase I clinical trial

1 reference

L N Shulman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

L Buswell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N Riese

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N Doherty

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J S Loeffler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

R W von Roemeling

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

C N Coleman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 May 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

349-353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

The histological structure of some human lung cancers and the possible implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Therapeutic advantage of hypoxic cells in tumors: a theoretical study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900016-4

7 January 2021

10.1016/S0360-3016(99)00016-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10760430%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference